Table 2.

Cumulative Incidence of Competing Risks for Patients in the Acute, Chronic and Combined Phases of Anticoagulation^*

	Acute Phase N=59	Chronic Phase N=138	Combined Period N=163
Ischemic Stroke (95% CI)	0	1.8% (0–4.3)	1.4% (0–3.4)
Major bleeding (95% CI)	0	1.5% (0–3.6)	1.2% (0–2.9)
Death (95% CI)	11.4% (1.4–20.3)	14.2% (7.3–20.5)	22.6% (12.2–31.7)
CRNMB (95% CI)	9.8% (0.2–18.4)	5.4% (1.1–9.5)	14.0% (4.2–22.7)

^*Cumulative incidence estimates for the chronic phase are conditional to reaching day 90 of anticoagulation without sustaining an event. The chronic phase was defined as lasting 275 days and the combined period encompasses 365 days.

CRNMB: Clinically-relevant non-major bleeding leading to discontinuation of rivaroxaban for at least 7 days.